Yttrium-90 Radioembolization for HCC: The Lancet Regional Health | July 2026

Introduction:

Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective multicenter study evaluated the real-world effectiveness, safety, quality of life, and survival outcomes of Y90 radioembolization.

Why was this study needed?

• High-quality prospective real-world data on Y90 radioembolization are limited.
• Current international guidelines differ regarding the role of Y90 in HCC.
• The impact of personalized dosimetry on survival remains uncertain.
• More evidence is needed in patients with portal vein tumor thrombosis (PVT).
• The potential role of Y90 as a bridge to curative surgery requires further validation.

Results:

• Y90 radioembolization achieved encouraging overall survival with a favorable safety profile across all BCLC stages, including patients with portal vein tumor thrombosis.
• Higher radiation doses to the tumor (especially ≥400 Gy) were associated with significantly longer survival, supporting personalized dosimetry-guided treatment.
• Approximately 1 in 10 patients were successfully downstaged to curative surgery after Y90, achieving excellent long-term survival, while quality of life remained well preserved.

Clinical Impact:

This landmark real-world study strengthens the role of dosimetry-guided Y90 radioembolization as an effective and safe treatment for selected patients with HCC. It also highlights Y90 as an important downstaging strategy before curative surgery and supports broader incorporation into future treatment guidelines.

Bottom Line:

Personalized Y90 radioembolization delivers meaningful survival with low toxicity in HCC. Higher tumor radiation doses improve outcomes, and successful downstaging to surgery offers the best long-term survival, reinforcing the importance of dosimetry-guided treatment planning.